Feb 11 (Reuters) - CSL Ltd (CSL) :
- PRIVIGEN® (IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% LIQUID) GRANTED ORPHAN-DRUG DESIGNATION FOR THE INVESTIGATIONAL TREATMENT OF SYSTEMIC SCLEROSIS (SSC)
Feb 11 (Reuters) - CSL Ltd (CSL) : PRIVIGEN® (IMMUNE GLOBULIN...
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$277.05 |
Change
-2.850(1.02%) |
Mkt cap ! $133.8B | |||
| Open | High | Low | Value | Volume |
| $276.54 | $277.10 | $275.10 | $171.7M | 621.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11515 | $277.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $277.08 | 1018 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$276.38 |
Change
-2.850 ( 1.16 %) |
||||
| Open | High | Low | Volume | ||
| $276.80 | $277.10 | $275.12 | 61725 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| CSL (ASX) Chart |